Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | BAD | Q92934 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30777455 | 1.00 | BCL2L1 (0.45) | BCL2L1BADMEN1KMT2ALMNA | |
| SCHEMBL1044992 | 0.96 | BCL2L1 (0.50) | BCL2L1BADMEN1KMT2ALMNA | |
| SCHEMBL19249411 | 0.94 | BCL2L1 (0.48) | BCL2L1BADMEN1KMT2ALMNA | |
| Dimethylamine SCHEMBL6542151 | 0.89 | BCL2L1 (0.44) | BCL2L1BADMEN1KMT2ALMNA | |
| SCHEMBL3453685 | 0.83 | ALDH1A1 (0.43) | BCL2L1BADMEN1KMT2ALMNA | |
| SCHEMBL3453076 | 0.80 | BCL2L1 (0.43) | BCL2L1BADMEN1KMT2ALMNA | |
| SCHEMBL231793 | 0.79 | BCL2L1 (0.45) | BCL2L1BADMEN1KMT2ALMNA | |
| SCHEMBL27726086 | 0.76 | BCL2L1 (0.39) | BCL2L1BADMEN1KMT2ALMNA | |
| SCHEMBL9136887 | 0.75 | BCL2L1 (0.50) | BCL2L1BADMEN1KMT2ALMNA | |
| SCHEMBL11741399 | 0.75 | CYP2A6 (0.46) | MEN1KMT2ALMNATHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110268538-A | Hole mobile material and the photovoltaic devices for using the hole mobile material | 埃尼股份公司 | 2019-09-20 | — | — | CN | claimed |
| CN-110235263-A | Polymer photovoltaic cell and its preparation process with inverted structure | 埃尼股份公司 | 2019-09-13 | — | — | CN | claimed |
| CN-104297373-B | A kind of tsaoko and fingerprint discrimination method in one's early teens | GUANGXI UNIVERSITY OF CHINESE MEDICINE (CN) | 2016-04-06 | — | — | CN | claimed |
| CN-104297373-A | Fingerprint chromatogram identification method of amomum tsaoko and alpinia katsumadai | UNIV GUANGXI CHINESE MEDICINE | 2015-01-21 | — | — | CN | claimed |
| US-3968163-A | Preparation of 4 and 5-methylindanes | MARION LABORATORIES, INC. (US) | 1976-07-06 | — | — | US | claimed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| CN-113272299-B | Moisture-curable polyurethane compositions comprising oxazolidines | SIKA技术股份公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| CN-110536880-B | Process for producing indanecarbaldehyde | 三菱瓦斯化学株式会社 | 2022-07-05 | — | — | CN | disclosed |
| EP-3898619-A1 | MOISTURE-CURING POLYURETHANE COMPOSITION CONTAINING OXAZOLIDINE | Sika Technology AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3880659-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-0518818-A2 | Arylethers, their manufacture and use as medicament | CIBA-GEIGY AG (CH) | 1992-12-16 | — | — | EP | disclosed |
| US-4438277-A | Hydronaphthalene derivatives | SANKYO COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
| US-4071562-A | 4,5-Dialkoxy-6 or 7-indanaldehydes | MARION LABORATORIES, INC. (US) | 1978-01-31 | — | — | US | disclosed |
| US-4071562-A | 4,5-Dialkoxy-6 or 7-indanaldehydes | MARION LABORATORIES, INC. (US) | 1978-01-31 | — | — | US | disclosed |
| US-3968163-A | Preparation of 4 and 5-methylindanes | MARION LABORATORIES, INC. (US) | 1976-07-06 | — | — | US | disclosed |
| US-3968163-A | Preparation of 4 and 5-methylindanes | MARION LABORATORIES, INC. (US) | 1976-07-06 | — | — | US | disclosed |
| US-3963723-A | HYPOTENSIVE | MARION LABORATORIES, INC. (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | BCL2L1 4249/4885BAD 4265/4885MEN1 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.